School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.
Int J Mol Sci. 2024 Jan 29;25(3):1633. doi: 10.3390/ijms25031633.
Despite significant advancements in understanding the causes and progression of tumors, cancer remains one of the leading causes of death worldwide. In light of advances in cancer therapy, there has been a growing interest in drug repurposing, which involves exploring new uses for medications that are already approved for clinical use. One such medication is edaravone, which is currently used to manage patients with cerebral infarction and amyotrophic lateral sclerosis. Due to its antioxidant and anti-inflammatory properties, edaravone has also been investigated for its potential activities in treating cancer, notably as an anti-proliferative and cytoprotective drug against side effects induced by traditional cancer therapies. This comprehensive review aims to provide updates on the various applications of edaravone in cancer therapy. It explores its potential as a standalone antitumor drug, either used alone or in combination with other medications, as well as its role as an adjuvant to mitigate the side effects of conventional anticancer treatments.
尽管人们在了解肿瘤的病因和发展方面取得了重大进展，但癌症仍然是全球主要的死亡原因之一。鉴于癌症治疗的进展，人们对药物再利用越来越感兴趣，这涉及到探索已经批准临床使用的药物的新用途。依达拉奉就是这样一种药物，它目前用于治疗脑梗死和肌萎缩侧索硬化症患者。由于其抗氧化和抗炎特性，依达拉奉也因其在治疗癌症方面的潜在活性而被研究，特别是作为一种抗增殖和细胞保护药物，可对抗传统癌症治疗引起的副作用。本综述旨在提供有关依达拉奉在癌症治疗中的各种应用的最新信息。它探讨了依达拉奉作为一种独立的抗肿瘤药物的潜力，无论是单独使用还是与其他药物联合使用，以及作为减轻传统抗癌治疗副作用的辅助药物的作用。
